<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086423</url>
  </required_header>
  <id_info>
    <org_study_id>112584</org_study_id>
    <nct_id>NCT01086423</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib™) in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the immunogenicity and reactogenicity of
      Infanrix-IPV/Hib™ vaccine when administered to healthy Chinese infants at 2, 3 and 4 or 3, 4
      and 5 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1, 2010</start_date>
  <completion_date type="Actual">November 19, 2010</completion_date>
  <primary_completion_date type="Actual">November 19, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens</measure>
    <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
    <description>A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigen</measure>
    <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
    <description>A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (μg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 Antigens</measure>
    <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
    <description>A seroprotected subject was defined as a subject with anti-poliovirus (anti-polio) types 1, 2 and 3 antibody titres ≥ the value of 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With a Vaccine Response to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antibodies</measure>
    <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
    <description>Vaccine response was defined as:
For PT and FHA response, antibody concentration ≥ 20 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at post-vaccination.
For PRN response: for initially seronegative subjects [antibody concentration lower than (&lt;) 5 EL.U/mL], post-vaccination antibody concentration ≥ 20 EL.U/mL; for initially seropositive subjects (antibody concentration ≥ 5 EL.U/mL), at least a 4-fold increase in antibody concentration from pre to post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-D and Anti-T Antibody Concentrations</measure>
    <time_frame>Before the first dose (Month 0) and one month after the third dose of vaccination (Month 3 or Month 4)</time_frame>
    <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP Antibody Concentrations</measure>
    <time_frame>Before the first dose (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)</time_frame>
    <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-polio Types 1, 2 and 3 Antibody Titers</measure>
    <time_frame>Before the first dose (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)</time_frame>
    <description>Antibody titers were presented as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</measure>
    <time_frame>Before (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)</time_frame>
    <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited Local Symptoms</measure>
    <time_frame>During the 4-day (Days 0-3) post-vaccination period after each vaccine dose and across doses</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited General Symptoms</measure>
    <time_frame>During the 4-day (Days 0-3) post-vaccination period after each vaccine dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 37.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31-day (Days 0-30) post-vaccination period after any dose</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (from Month 0 to Month 4/5)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">985</enrollment>
  <condition>Tetanus</condition>
  <condition>Poliomyelitis</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Diphtheria</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>INFANRIX-IPV+HIB 1 GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INFANRIX-IPV+HIB 2 GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INFANRIX-HIB+POLIORIX GROUP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix-IPV/Hib™</intervention_name>
    <description>Intramuscular, three doses</description>
    <arm_group_label>INFANRIX-IPV+HIB 2 GROUP</arm_group_label>
    <arm_group_label>INFANRIX-IPV+HIB 1 GROUP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix Hib™</intervention_name>
    <description>Intramuscular, three doses</description>
    <arm_group_label>INFANRIX-HIB+POLIORIX GROUP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Poliorix™</intervention_name>
    <description>Intramuscular, three doses</description>
    <arm_group_label>INFANRIX-HIB+POLIORIX GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female infant between, and including, 60 and 90 days of age at the time of
             the first study visit.

          -  Born after a gestation period of 36 to 42 weeks, inclusive.

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LAR) can and will comply with the requirements of the protocol.

          -  Written informed consent obtained from the parent(s) or LAR(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Child in care.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Administration of a vaccine not foreseen by the study protocol within 30 days prior to
             vaccination, or planned administration during the study period, with the exception of
             hepatitis B vaccine.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis
             and/or Haemophilus influenzae type b (Hib) disease or vaccination.

          -  History of seizures or progressive neurological disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine(s).

          -  Major congenital defects or serious chronic illness.

        The following condition is temporary or self-limiting and a subject may be vaccinated once
        the condition has resolved and no other exclusion criteria are met:

        • Current febrile illness or axillary temperature &gt; 37.0°C or other moderate to severe
        illness within 24 hours of study vaccine administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuzhou</city>
        <state>Guangxi</state>
        <zip>543002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuzhou</city>
        <state>Guangxi</state>
        <zip>543100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <results_first_submitted>February 24, 2017</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <disposition_first_submitted>December 23, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>December 23, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 30, 2010</disposition_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infanrix-IPV+Hib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One subject did not receive vaccination.</recruitment_details>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Infanrix-IPV+Hib 1 Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
        </group>
        <group group_id="P2">
          <title>Infanrix-IPV+Hib 2 Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
        </group>
        <group group_id="P3">
          <title>Infanrix-Hib+Poliorix Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="324"/>
                <participants group_id="P3" count="330"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="320"/>
                <participants group_id="P2" count="321"/>
                <participants group_id="P3" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event, fatal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event, non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infanrix-IPV+Hib 1 Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
        </group>
        <group group_id="B2">
          <title>Infanrix-IPV+Hib 2 Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
        </group>
        <group group_id="B3">
          <title>Infanrix-Hib+Poliorix Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="330"/>
            <count group_id="B2" value="324"/>
            <count group_id="B3" value="330"/>
            <count group_id="B4" value="984"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="1.12"/>
                    <measurement group_id="B2" value="14.3" spread="1.14"/>
                    <measurement group_id="B3" value="9.9" spread="1.17"/>
                    <measurement group_id="B4" value="11.35" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian-Chinese heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="324"/>
                    <measurement group_id="B3" value="330"/>
                    <measurement group_id="B4" value="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens</title>
        <description>A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).</description>
        <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens</title>
          <description>A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™ -IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-D, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.88</ci_lower_limit>
            <ci_upper_limit>3.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-T, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigen</title>
        <description>A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (μg/mL).</description>
        <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigen</title>
          <description>A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (μg/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-PRP antibodies, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>-7.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.44</ci_lower_limit>
            <ci_upper_limit>-2.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 Antigens</title>
        <description>A seroprotected subject was defined as a subject with anti-poliovirus (anti-polio) types 1, 2 and 3 antibody titres ≥ the value of 8.</description>
        <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 Antigens</title>
          <description>A seroprotected subject was defined as a subject with anti-poliovirus (anti-polio) types 1, 2 and 3 antibody titres ≥ the value of 8.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-polio 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-Polio type 1 antibodies, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-Polio type 2 antibodies, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-Polio type 3 antibodies, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Vaccine Response to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antibodies</title>
        <description>Vaccine response was defined as:
For PT and FHA response, antibody concentration ≥ 20 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at post-vaccination.
For PRN response: for initially seronegative subjects [antibody concentration lower than (&lt;) 5 EL.U/mL], post-vaccination antibody concentration ≥ 20 EL.U/mL; for initially seropositive subjects (antibody concentration ≥ 5 EL.U/mL), at least a 4-fold increase in antibody concentration from pre to post-vaccination.</description>
        <time_frame>One month after the third vaccine dose (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Vaccine Response to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antibodies</title>
          <description>Vaccine response was defined as:
For PT and FHA response, antibody concentration ≥ 20 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at post-vaccination.
For PRN response: for initially seronegative subjects [antibody concentration lower than (&lt;) 5 EL.U/mL], post-vaccination antibody concentration ≥ 20 EL.U/mL; for initially seropositive subjects (antibody concentration ≥ 5 EL.U/mL), at least a 4-fold increase in antibody concentration from pre to post-vaccination.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-PT antigens, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.74</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-FHA antigens, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% CI on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.75</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate that the immunogenicity of Infanrix™-IPV+Hib vaccine administered at 2, 3 and 4 months of age was non-inferior to that of the concomitant administration of Infanrix™-Hib and Poliorix™ vaccines at the same age, in terms of immune response to anti-PRN antigens, one month after the third vaccine dose.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for evaluation of Non-inferiority: The UL of the standardized asymptotic 95% confidence interval (CI) on the group difference [Infanrix-Hib + Poliorix Group minus Infanrix-IPV+Hib 1 Group] in percentage of seroprotected subjects ≤ 10%.</non_inferiority_desc>
            <param_type>Difference in seroprotection rate</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-D and Anti-T Antibody Concentrations</title>
        <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.</description>
        <time_frame>Before the first dose (Month 0) and one month after the third dose of vaccination (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-D and Anti-T Antibody Concentrations</title>
          <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" lower_limit="0.05" upper_limit="0.053"/>
                    <measurement group_id="O2" value="0.051" lower_limit="0.05" upper_limit="0.052"/>
                    <measurement group_id="O3" value="0.051" lower_limit="0.049" upper_limit="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.719" lower_limit="0.661" upper_limit="0.782"/>
                    <measurement group_id="O2" value="0.753" lower_limit="0.699" upper_limit="0.812"/>
                    <measurement group_id="O3" value="0.613" lower_limit="0.565" upper_limit="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" lower_limit="0.05" upper_limit="0.052"/>
                    <measurement group_id="O2" value="0.052" lower_limit="0.05" upper_limit="0.054"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.05" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.118" lower_limit="3.779" upper_limit="4.488"/>
                    <measurement group_id="O2" value="4.124" lower_limit="3.796" upper_limit="4.479"/>
                    <measurement group_id="O3" value="3.618" lower_limit="3.339" upper_limit="3.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRP Antibody Concentrations</title>
        <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.</description>
        <time_frame>Before the first dose (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PRP Antibody Concentrations</title>
          <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" lower_limit="0.104" upper_limit="0.154"/>
                    <measurement group_id="O2" value="0.135" lower_limit="0.112" upper_limit="0.163"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.122" upper_limit="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.601" lower_limit="4.676" upper_limit="6.709"/>
                    <measurement group_id="O2" value="9.396" lower_limit="8.032" upper_limit="10.992"/>
                    <measurement group_id="O3" value="2.826" lower_limit="2.235" upper_limit="3.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-polio Types 1, 2 and 3 Antibody Titers</title>
        <description>Antibody titers were presented as geometric mean titers (GMTs).</description>
        <time_frame>Before the first dose (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polio Types 1, 2 and 3 Antibody Titers</title>
          <description>Antibody titers were presented as geometric mean titers (GMTs).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-polio 1, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="7.7" upper_limit="11.5"/>
                    <measurement group_id="O2" value="7.1" lower_limit="6.2" upper_limit="8.2"/>
                    <measurement group_id="O3" value="9.2" lower_limit="7.7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 1, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1143.7" lower_limit="952.7" upper_limit="1372.9"/>
                    <measurement group_id="O2" value="1328.9" lower_limit="1137.6" upper_limit="1552.4"/>
                    <measurement group_id="O3" value="533.6" lower_limit="469.5" upper_limit="606.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 2, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.5" upper_limit="7.2"/>
                    <measurement group_id="O2" value="5" lower_limit="4.6" upper_limit="5.5"/>
                    <measurement group_id="O3" value="6.9" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 2, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.2" lower_limit="344.5" upper_limit="502.8"/>
                    <measurement group_id="O2" value="458.6" lower_limit="385.6" upper_limit="545.5"/>
                    <measurement group_id="O3" value="186.4" lower_limit="160.4" upper_limit="216.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 3, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5" upper_limit="6.8"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.3" upper_limit="5.6"/>
                    <measurement group_id="O3" value="5.7" lower_limit="5.1" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-polio 3, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1478.8" lower_limit="1210.6" upper_limit="1806.5"/>
                    <measurement group_id="O2" value="1411.6" lower_limit="1175.3" upper_limit="1695.3"/>
                    <measurement group_id="O3" value="820.7" lower_limit="820.7" upper_limit="964.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
        <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.</description>
        <time_frame>Before (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
          <description>Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included a subset of evaluable subjects for whom data concerning immunogenicity outcome measures and assay results for antibodies against at least one study vaccine antigen component were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.8" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.6" upper_limit="2.8"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.6" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.7" lower_limit="99.2" upper_limit="119.1"/>
                    <measurement group_id="O2" value="114.7" lower_limit="105.4" upper_limit="124.8"/>
                    <measurement group_id="O3" value="97.1" lower_limit="88.3" upper_limit="106.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, M0 [</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.7" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.5" upper_limit="2.7"/>
                    <measurement group_id="O3" value="2.9" lower_limit="2.7" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="79.9" upper_limit="96.3"/>
                    <measurement group_id="O2" value="87.6" lower_limit="79.6" upper_limit="96.4"/>
                    <measurement group_id="O3" value="76.3" lower_limit="68.5" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, M0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.5" upper_limit="2.7"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.5" upper_limit="2.6"/>
                    <measurement group_id="O3" value="2.5" lower_limit="2.5" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN, M3/M4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="42" upper_limit="47.9"/>
                    <measurement group_id="O2" value="43.7" lower_limit="41.3" upper_limit="46.3"/>
                    <measurement group_id="O3" value="43.2" lower_limit="39.8" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>During the 4-day (Days 0-3) post-vaccination period after each vaccine dose and across doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented, who had their symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented, who had their symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 37.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to study vaccination.</description>
        <time_frame>During the 4-day (Days 0-3) post-vaccination period after each vaccine dose and across doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented, who had their symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 37.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented, who had their symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever/Axillary, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever/Axillary, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever/Axillary, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever/Axillary, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="217"/>
                    <measurement group_id="O3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) post-vaccination period after any dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (from Month 0 to Month 4/5)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix-IPV+Hib 1 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix-IPV+Hib 2 Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
          </group>
          <group group_id="O3">
            <title>Infanrix-Hib+Poliorix Group</title>
            <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period. Unsolicited AEs: during the 31-day (Days 0-30) post-vaccination period. SAEs: during the entire study period (from Month 0 up to Month 4/5).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infanrix-IPV+Hib 1 Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.</description>
        </group>
        <group group_id="E2">
          <title>Infanrix-IPV+Hib 2 Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.</description>
        </group>
        <group group_id="E3">
          <title>Infanrix-Hib+Poliorix Group</title>
          <description>Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="183" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Fever (Axillary)</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="183" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="324"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

